SCHEMBL12879133

SCHEMBL12879133

COCCN(CCOC)C(=O)c1ncn([C@@H]2O[C@H](CO)[C@H](O)C2O)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ ALDH1A1 P00352 3/20 0.61
▸ TSHR P16473 2/20 0.61
▸ THPO P40225 2/20 0.61
▸ PMP22 Q01453 2/20 0.61
▸ GLA P06280 1/20 0.61
▸ EIF4E P06730 1/20 0.61
▸ CYP3A4 P08684 1/20 0.61
▸ TOP1 P11387 1/20 0.61
▸ ADORA1 P30542 1/20 0.61
▸ PNP P00491 3/20 0.56
▸ KDM4E B2RXH2 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ BLM P54132 2/20 0.39
▸ TP53 P04637 2/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ GMNN O75496 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12879156 1.00 LMNA (0.61) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL12879155 0.83 LMNA (0.41) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL12879137 0.82 LMNA (0.63) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL12879145 0.82 LMNA (0.63) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL27568954 0.81 LMNA (0.71) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL2841654 0.81 LMNA (0.71) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL27568953 0.81 LMNA (0.71) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL2845582 0.79 LMNA (0.76) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL13352082 0.79 LMNA (0.76) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL12901991 0.79 LMNA (0.76) LMNASMN1; SMN2ALDH1A1TSHRTHPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8466276-B2 Oligomer conjugates of heteropentacyclic nucleosides NEKTAR THERAPEUTICS (US) 2013-06-18 — — US disclosed
US-20110039797-A1 Oligomer Conjugates of Heteropentacyclic Nucleosides Nektar Therapetics (US) 2011-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039797-A1 Oligomer Conjugates of Heteropentacyclic Nucleosides SLC29A2, SLC29A1, GNE LMNA 3873/4885SMN1; SMN2 2799/4885ALDH1A1 2313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback